Physician profile
Reza Samad
NPI 1265674683
$1,427.80
in general payments reported to CMS, 2019-2025
14 companies · $21.93 in 2025
The $21.93 reported for 2025 was less than what a typical Neurocritical Care provider received nationally (typical 2025 total: $95.82).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.00 · 2020: $12.73 · 2021: $154 · 2022: $709 · 2023: $485 · 2024: $30.22 · 2025: $21.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $298.56 | 2022-2023 | Tezspire, Symbicort, Fasenra |
| Pulmonx Corporation | $287.76 | 2022-2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Glaxosmithkline, LLC. | $257.25 | 2020-2024 | Nucala, Trelegy Ellipta |
| Inari Medical, INC. | $143.59 | 2022 | |
| Amgen INC. | $141.34 | 2022 | |
| Philips North America LLC | $58.48 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.02 | 2022-2023 | Ofev |
| Mylan Specialty L.P. | $45.32 | 2022-2023 | Yupelri |
| Genzyme Corporation | $33.07 | 2023-2024 | |
| United Therapeutics Corporation | $28.62 | 2023 | Tyvaso, Orenitram |
| Mallinckrodt Hospital Products INC. | $28.12 | 2022-2023 | Acthar |
| Edwards Lifesciences Corporation | $22.74 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbvie INC. | $21.93 | 2025 | |
| Astellas Pharma US INC | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reza Samad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.